Molecular Landscape and Emerging Therapeutic Strategies in Breast Cancer Brain Metastasis

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2023 Apr 10

PMID 37034479

Authors

Siyi Xiong

Xuanni Tan

Xiujuan Wu

Andi Wan

Guozhi Zhang

Cheng Wang

Yan Liang

Yi Zhang

Affiliations

Soon will be listed here.

Abstract

Breast cancer (BC) is the most commonly diagnosed cancer worldwide. Advanced BC with brain metastasis (BM) is a major cause of mortality with no specific or effective treatment. Therefore, better knowledge of the cellular and molecular mechanisms underlying breast cancer brain metastasis (BCBM) is crucial for developing novel therapeutic strategies and improving clinical outcomes. In this review, we focused on the latest advances and discuss the contribution of the molecular subtype of BC, the brain microenvironment, exosomes, miRNAs/lncRNAs, and genetic background in BCBM. The blood-brain barrier and blood-tumor barrier create challenges to brain drug delivery, and we specifically review novel approaches to bypass these barriers. Furthermore, we discuss the potential application of immunotherapies and genetic editing techniques based on CRISPR/Cas9 technology in treating BCBM. Emerging techniques and research findings continuously shape our views of BCBM and contribute to improvements in precision therapies and clinical outcomes.

Citing Articles

Early death prediction model for breast cancer with synchronous lung metastases: an analysis of the SEER database.

Li Q, Sun T, Zhang Z Gland Surg. 2024; 13(10):1708-1728.

PMID: 39544977 PMC: 11558301. DOI: 10.21037/gs-24-240.

References

Kuksis M, Gao Y, Tran W, Hoey C, Kiss A, Komorowski A . The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. Neuro Oncol. 2020; 23(6):894-904. PMC: 8168821. DOI: 10.1093/neuonc/noaa285. View

Chhichholiya Y, Suman P, Singh S, Munshi A . The genomic architecture of metastasis in breast cancer: focus on mechanistic aspects, signalling pathways and therapeutic strategies. Med Oncol. 2021; 38(8):95. DOI: 10.1007/s12032-021-01547-1. View

Boire A, Brastianos P, Garzia L, Valiente M . Brain metastasis. Nat Rev Cancer. 2019; 20(1):4-11. DOI: 10.1038/s41568-019-0220-y. View

Murthy R, Borges V, Conlin A, Chaves J, Chamberlain M, Gray T . Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018; 19(7):880-888. DOI: 10.1016/S1470-2045(18)30256-0. View

Vanlandewijck M, He L, Mae M, Andrae J, Ando K, Del Gaudio F . A molecular atlas of cell types and zonation in the brain vasculature. Nature. 2018; 554(7693):475-480. DOI: 10.1038/nature25739. View

Ngamcherdtrakul W, Bejan D, Cruz-Munoz W, Reda M, Zaidan H, Siriwon N . Targeted Nanoparticle for Co-delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis. Small. 2022; 18(11):e2107550. PMC: 8959011. DOI: 10.1002/smll.202107550. View

Watase C, Shiino S, Shimoi T, Noguchi E, Kaneda T, Yamamoto Y . Breast Cancer Brain Metastasis-Overview of Disease State, Treatment Options and Future Perspectives. Cancers (Basel). 2021; 13(5). PMC: 7959316. DOI: 10.3390/cancers13051078. View

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P . Breast cancer. Nat Rev Dis Primers. 2019; 5(1):66. DOI: 10.1038/s41572-019-0111-2. View

Fares J, Ulasov I, Timashev P, Lesniak M . Emerging principles of brain immunology and immune checkpoint blockade in brain metastases. Brain. 2021; 144(4):1046-1066. PMC: 8105040. DOI: 10.1093/brain/awab012. View

10.

Kumthekar P, Tang S, Brenner A, Kesari S, Piccioni D, Anders C . ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clin Cancer Res. 2020; 26(12):2789-2799. DOI: 10.1158/1078-0432.CCR-19-3258. View

11.

Steeg P . The blood-tumour barrier in cancer biology and therapy. Nat Rev Clin Oncol. 2021; 18(11):696-714. DOI: 10.1038/s41571-021-00529-6. View

12.

Bebelman M, Smit M, Pegtel D, Baglio S . Biogenesis and function of extracellular vesicles in cancer. Pharmacol Ther. 2018; 188:1-11. DOI: 10.1016/j.pharmthera.2018.02.013. View

13.

Yang F, Cui P, Lu Y, Zhang X . Requirement of the transcription factor YB-1 for maintaining the stemness of cancer stem cells and reverting differentiated cancer cells into cancer stem cells. Stem Cell Res Ther. 2019; 10(1):233. PMC: 6679460. DOI: 10.1186/s13287-019-1360-4. View

14.

Abbott N, Patabendige A, Dolman D, Yusof S, Begley D . Structure and function of the blood-brain barrier. Neurobiol Dis. 2009; 37(1):13-25. DOI: 10.1016/j.nbd.2009.07.030. View

15.

Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, Hasegawa T . Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer. 2009; 116(2):302-8. DOI: 10.1002/cncr.24735. View

16.

Kim J, Kim B, Jang Y, Kang S, Lee J, Cho N . The stromal loss of miR-4516 promotes the FOSL1-dependent proliferation and malignancy of triple negative breast cancer. Cancer Lett. 2019; 469:256-265. DOI: 10.1016/j.canlet.2019.10.039. View

17.

Sereno M, Videira M, Wilhelm I, Krizbai I, Brito M . miRNAs in Health and Disease: A Focus on the Breast Cancer Metastatic Cascade towards the Brain. Cells. 2020; 9(8). PMC: 7463742. DOI: 10.3390/cells9081790. View

18.

Harati R, Hafezi S, Mabondzo A, Tlili A . Silencing miR-202-3p increases MMP-1 and promotes a brain invasive phenotype in metastatic breast cancer cells. PLoS One. 2020; 15(10):e0239292. PMC: 7529272. DOI: 10.1371/journal.pone.0239292. View

19.

Graham M, Mellinghoff I . Meningeal lymphatics prime tumor immunity in glioblastoma. Cancer Cell. 2021; 39(3):304-306. PMC: 9549925. DOI: 10.1016/j.ccell.2021.02.012. View

20.

Boix-Montesinos P, Soriano-Teruel P, Arminan A, Orzaez M, Vicent M . The past, present, and future of breast cancer models for nanomedicine development. Adv Drug Deliv Rev. 2021; 173:306-330. PMC: 8191594. DOI: 10.1016/j.addr.2021.03.018. View